ACOG

Alpha Cognition is a newly commercial-stage biopharma whose entire investment case rests on one product: ZUNVEYL, a next-generation acetylcholinesterase inhibitor launched into long-term-care nursing homes on March 19, 2025. FY2025 is therefore a partial launch year, and the $10.2M of first-year revenue against a full commercial cost base explains the grotesque-looking margins (operating margin -221.7%, net margin -202.2%). Those ratios are a launch artifact, not evidence of a broken model — but they also mean there is not yet any proof of profitable scale. The MD&A is candid that operations are 'highly dependent upon its ability to obtain additional funding' and that management 'will need to raise additional capital' to fund R&D, continued ZUNVEYL commercialization and operating costs, tapping its at-the-market facility, private placements, public offerings and warrant exercises. That is the central risk: dilution. Shares already grew +35.9% YoY, and the funding language signals more to come.

What keeps this from an outright avoid is the balance sheet, which is genuinely healthy for a micro-cap biotech. The company holds $66.0M in cash and equivalents against just $9.13M of current liabilities and $17.2M of total liabilities, with a liabilities/equity ratio of only 0.28x and $62.5M of stockholders' equity. At a ~$20.4M annual operating cash burn, that is roughly three years of runway before any further raise — a real cushion, even if management still flags the need for more capital. The accumulated deficit of $97.1M underscores how much equity has been consumed to get here, but the company is not levered or distressed.